New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
13:20 EDTINCYIncyte June volatility elevated into ASCO
Incyte June call option implied volatility is at 79, July is at 60, September is at 58, compared to its 26-week average of 64 according to Track Data, suggesting large near term price movement into discussion of RESPONSE: Phase 3 Trial of Ruxolitinib in PV at ASCO.
News For INCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 4, 2015
07:15 EDTINCYIncyte lowers FY15 Jakafi revenue view to $525M-$565M from $560M-$575M
Lowers FY15 R&D expenses view to $450M-$500M from $475M-$500M. Lowers FY15 selling, general, and administrative expenses view to $180M-$200M from $195M-$210M.
07:12 EDTINCYIncyte reports Q2 EPS 5c, consensus (11c)
Subscribe for More Information
August 3, 2015
08:55 EDTINCYIncyte price target raised to $125 from $115 at Leerink
Leerink raised its price target for Incyte to $125 saying its survey of 49 U.S. hematologists indicated Jakafi has blockbuster potential in polycythemia vera. The firm keeps an Outperform rating on the stock.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use